Media Thread, page-13516

She doesn't know why the SP is 8c? She obviously hasn't seen Rock Robster's post.

Funny how Leslie knows all about the bile duct patient who went into remission, but apparently nothing about a patient who almost died after the IMU treatment, and who is now in the unfortunate position of not being able to access other treatments. Its so sad for the patient.

The patient knows that the trial protocol is being changed - which at best means delays - and IMU makes no announcement?

And for those trying to explain away the adverse reaction due to it being the 4th line of therapy - unless your drug is safe and shows signs of efficacy on patients using it as a 3rd, 4th, 5th line of treatment, you don't get to try it on anyone as a first line. So if many other patients suffer Rock Robster's fate, IMU won't be afforded the chance of finding out whether the adverse reaction occurred due to previous treatments.

The thing about the IMU SP is that it tracks entirely objectively. Every time one of IMU's sciences fail or prove less safe or less effective than hoped, the stock re-rates. It does exactly what Leslie says - it follows the science.

Unfortunately for shareholders they need to find out the hard way, and long after those that benefit from the leaky ship have divested.

Here's what's happened since Rock Robsters post. IMU has followed the science as opposed to the indexes.




The company in grey has also followed the science. It announced that a patient that was treated with its product - as a 5th line of treatment, at less than the therapeutic dose, by virtue of the FDA's expanded access program, had no sign of cancer after the treatment and has continued to show no signs of cancer 5 months later.